Organigram Product Development Collaboration Completes Landmark Clinical Study on Nanoemulsion Technology
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) has completed a landmark clinical pharmacokinetic study on its FAST™ (Fast Acting Soluble Technology) nanoemulsion technology. The study, conducted through the Product Development Collaboration, revealed promising results:
1. Up to 50% faster onset of cannabis effects compared to traditional ingestibles
2. Improved bioavailability with up to double the cannabinoid delivery at peak
3. Potential for more predictable duration of effects
Organigram plans to leverage this data to substantiate functional technology claims and expects to commercialize FAST™ in fall 2024, starting with gummies. The company views this innovation as a competitive advantage for its ingestible portfolio, addressing key consumer pain points in dosage control and experience predictability.
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) ha completato uno studio clinico farmacocinetico fondamentale sulla sua tecnologia nanoemulsione FAST™ (Fast Acting Soluble Technology). Lo studio, condotto attraverso la Collaborazione per lo Sviluppo del Prodotto, ha rivelato risultati promettenti:
1. Inizio degli effetti del cannabis fino al 50% più veloce rispetto ai tradizionali prodotti ingeribili
2. Maggiore biodisponibilità con un aumento fino a doppio della consegna di cannabinoidi al picco
3. Possibilità di una durata degli effetti più prevedibile
Organigram prevede di sfruttare questi dati per avvalorare le affermazioni tecnologiche funzionali e si aspetta di commercializzare FAST™ nella fall 2024, a partire dalle gomme. L'azienda considera questa innovazione un vantaggio competitivo per il suo portfolio di prodotti ingeribili, rispondendo a problematiche chiave dei consumatori riguardo al controllo del dosaggio e alla prevedibilità dell'esperienza.
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) ha completado un estudio clínico farmacocinético fundamental sobre su tecnología de nanoemulsión FAST™ (Fast Acting Soluble Technology). El estudio, realizado a través de la Colaboración para el Desarrollo del Producto, reveló resultados prometedores:
1. Hasta un 50% más rápido en la aparición de los efectos del cannabis en comparación con los productos ingeribles tradicionales
2. Mejor biodisponibilidad con hasta el doble de entrega de cannabinoides en el pico
3. Potencial para una duración de los efectos más predecible
Organigram planea aprovechar estos datos para respaldar las afirmaciones funcionales de la tecnología y espera comercializar FAST™ en fall 2024, comenzando con gomitas. La empresa considera esta innovación como una ventaja competitiva para su cartera de productos ingeribles, abordando puntos críticos de los consumidores en el control de dosis y la previsibilidad de la experiencia.
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI)은 FAST™ (Fast Acting Soluble Technology) 나노 에멀전 기술에 대한 획기적인 임상 약리학 연구를 완료했습니다. 제품 개발 협력을 통해 수행된 이번 연구 결과는 유망한 결과를 보여주었습니다:
1. 전통적인 섭취 제품에 비해 최대 50% 더 빠른 대마초 효과 발생
2. 정점에서 최대 두 배의 칸나비노이드 전달로 개선된 생체이용률
3. 더 예측 가능한 효과 지속 가능성
Organigram은 이 데이터를 활용하여 기능성 기술 주장을 입증할 계획이며 2024년 가을에 젤리형 제품으로 FAST™를 상용화할 것으로 기대하고 있습니다. 이 회사는 이 혁신을 섭취용 제품 포트폴리오의 경쟁 우위로 보고 있으며, 용량 조절과 경험 예측 가능성이라는 주요 소비자 문제를 해결하고자 합니다.
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) a achevé une étude clinique pharmacocinétique marquante sur sa technologie de nanoémulsion FAST™ (Fast Acting Soluble Technology). L'étude, réalisée à travers la Collaboration pour le Développement de Produit, a révélé des résultats prometteurs :
1. Apparition des effets du cannabis jusqu'à 50 % plus rapide par rapport aux produits à ingérer traditionnels
2. Amélioration de la biodisponibilité avec jusqu'à deux fois plus de livraison de cannabinoïdes au pic
3. Potentiel pour une durée des effets plus prévisible
Organigram prévoit d'exploiter ces données pour étayer ses revendications technologiques fonctionnelles et s'attend à commercialiser FAST™ à partir de l'automne 2024, en commençant par des gommes. L'entreprise considère cette innovation comme un avantage concurrentiel pour son portefeuille de produits à ingérer, répondant aux principaux points de douleur des consommateurs en matière de contrôle des doses et de prévisibilité des expériences.
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) hat eine wegweisende klinische Pharmakokinetik-Studie zu seiner FAST™ (Fast Acting Soluble Technology) Nanoemulsionstechnologie abgeschlossen. Die Studie, die im Rahmen der Produktentwicklungskollaboration durchgeführt wurde, ergab vielversprechende Ergebnisse:
1. Bis zu 50% schnellere Wirkung von Cannabis-Effekten im Vergleich zu traditionellen oral eingenommenen Produkten
2. Verbesserte Bioverfügbarkeit mit bis zu doppelt so hoher Cannabinoidabgabe zum Höhepunkt
3. Möglichkeit einer besser vorhersehbaren Dauer der Effekte
Organigram plant, diese Daten zu nutzen, um funktionale Technologieansprüche zu untermauern, und erwartet, FAST™ im Herbst 2024 mit Gummis auf den Markt zu bringen. Das Unternehmen betrachtet diese Innovation als Wettbewerbsvorteil für sein Sortiment an oral eingenommenen Produkten, um zentrale Verbraucherprobleme in Bezug auf Dosierungssteuerung und Erfahrungsvorhersagbarkeit anzugehen.
- Completion of a landmark clinical pharmacokinetic study on FAST™ nanoemulsion technology
- Up to 50% faster onset of cannabis effects compared to traditional ingestibles
- Improved bioavailability with up to double the cannabinoid delivery at peak
- Potential for more predictable duration of effects
- Plans to commercialize FAST™ technology in fall 2024, starting with gummies
- Manufacturing scale-up trials for FAST™ gummies underway at Organigram's Winnipeg facility
- None.
Insights
The completion of Organigram's clinical pharmacokinetic study on nanoemulsion technology, branded as FAST™, represents a significant advancement in cannabis product development. Key findings include:
- Up to
50% faster onset of effects compared to traditional ingestibles - Up to double the cannabinoid delivery at peak
- Potential for more predictable duration of effects
These results could address major consumer pain points in the ingestible cannabis market, particularly regarding dosage control and predictability. The study's scale and design (19-day, 8-arm) lend credibility to the findings. However, it's important to note that the final report is not expected until October 2024 and regulatory approval for functional claims is still pending. The planned commercialization in fall 2024 aligns with the report's release, but market reception and regulatory hurdles remain uncertain factors in the technology's success.
Organigram's investment in FAST™ technology could potentially strengthen its market position in the competitive cannabis edibles sector. The improved bioavailability and faster onset of effects may justify premium pricing, potentially boosting profit margins. However, the financial impact remains speculative until product launch and consumer adoption.
Investors should consider:
- R&D costs and potential returns on this investment
- Market size for premium cannabis edibles
- Competitive landscape and potential for market share gains
- Regulatory risks associated with new cannabis technologies
While promising, it's important to await concrete financial projections and initial sales data post-launch to accurately assess the technology's impact on Organigram's bottom line.
The FAST™ technology addresses key consumer demands in the cannabis edibles market:
- Faster onset of effects
- Improved dosage control
- More predictable experience
These features could differentiate Organigram's products in a crowded market. The planned launch of gummies aligns with popular consumer preferences. However, success will depend on:
- Effective marketing to educate consumers on benefits
- Pricing strategy balancing premium features with affordability
- Distribution reach and retail partnerships
The collaboration with BAT through the PDC adds credibility and potential for international expansion. Yet, market acceptance remains uncertain until post-launch consumer feedback is available. Competitors' responses and potential similar innovations should also be monitored closely.
FAST™ Nanoemulsion Technology Expected to be a Competitive Advantage for Organigram’s Ingestible Portfolio
The clinical study was completed in January 2024, and the final data set has been received and reviewed. The final report is expected to be published in October 2024.
The results of the study have given early indications of technological advances, including but not limited to:
-
Faster onset compared to traditional ingestible products from the control group. Depending on ingestible format, up to approximately
50% faster onset of the effects of cannabis was observed. - Improved bioavailability of cannabinoids: up to double the cannabinoid delivery at peak compared to the control group.
- Early indicators of a more predictable duration of the effects of cannabis showing promising signals for the development of future offset claims, subject to additional supporting studies.
“We are thrilled with the study findings. The patent-pending nanoemulsion technology, FAST™, promises to unlock the power of the ingested cannabinoids and allow consumers to navigate and control their dosage experience more accurately – a key consumer pain point in the ingestible product space. These technological advances underscore Organigram’s commitment to consumers and to developing science-driven innovations” said Borna Zlamalik, SVP of Innovation and R&D.
Organigram has analyzed and intends to leverage the data to substantiate functional technology claims, adhering to Health Canada regulations. "As a responsible licensed producer, our aim is to thoroughly educate consumers about the effects of this technology, empowering them to enjoy a controlled and predictable ingestible experience,” added Mr. Zlamalik.
The study is believed to be one of the largest PK studies targeted at adult-use recreational cannabis products. The robust, 19-day in-clinic, eight-arm study executed by a leading third-party clinical research organization evaluated cannabinoid absorption across three key product formats to determine the effectiveness of the innovative delivery system.
Organigram expects to commercialize FAST™ in the fall of 2024, beginning with gummies. Manufacturing scale-up trials for these gummies are currently underway at Organigram’s
“Organigram has always been focused on consumer-centric innovation as one of its core differentiators and our commitment to the development of advanced technologies underscores this commitment,” said Beena Goldenberg, CEO of Organigram. “We are confident that our investment in this technology will pave the way for our continued success in the edibles space both here and in future abroad.”
*The Product Development Collaboration (“PDC”) is a joint collaboration between BAT and Organigram and was established to focus on developing next-generation cannabis products.
About Organigram
Organigram is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiary Organigram Inc. is a licensed producer of cannabis, cannabis-derived products and cannabis-infused edibles in
Organigram is focused on producing high-quality, cannabis for adult recreational consumers as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Laurentian, Tremblant Cannabis and Trailblazer. Organigram operates cultivation and manufacturing facilities in
Forward-Looking Information
This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release.
Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include factors and risks such as regulatory and market conditions, the outcome of commercialization efforts together with those factors and risks disclosed in the Company’s most recent annual information form, management’s discussion and analysis and other Company documents filed from time to time on SEDAR+ (see www.sedarplus.ca) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.
Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807039495/en/
For Media enquiries:
Megan McCrae
Senior Vice President of Global Brands and Corporate Affairs
megan.mccrae@organigram.ca
For Investor Relations enquiries:
Max Schwartz
Director of Investor Relations
investors@organigram.ca
Source: Organigram Holdings Inc.
FAQ
What is Organigram's FAST™ technology?
When will Organigram (OGI) launch products using FAST™ technology?
What were the key findings of Organigram's clinical study on FAST™ technology?
How does Organigram's FAST™ technology benefit consumers?
